Personalis, Inc. (PSNL)

Market Cap	1.72B +179.7%
Revenue (ttm)	80.77M +16.9%
Net Income	-119.33M
EPS	-1.17
Shares Out	108.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,755,222
Open	15.88
Previous Close	15.95
Day's Range	15.81 - 16.07
52-Week Range	4.96 - 18.89
Beta	2.36
Analysts	Hold
Price Target	15.17 (-4.47%)
Earnings Date	Nov 4, 2026

About PSNL

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample....

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 260
• Stock Exchange: Nasdaq
• Ticker Symbol: PSNL
• Website: https://www.personalis.com

Financial Performance

In 2025, Personalis's revenue was $69.65 million, a decrease of -17.69% compared to the previous year's $84.61 million. Losses were -$81.27 million, -0.02% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for PSNL stock is "Hold." The 12-month stock price target is $15.17, which is a decrease of -4.47% from the latest price.

Price Target

$15.17

(-4.47% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 10, 2026

Data Sources Report a data error